Emergent Biosolutions (NYSE:EBS) Stock Price Crosses Above 200 Day Moving Average – What’s Next?

Emergent Biosolutions Inc. (NYSE:EBS)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.65 and traded as high as $12.58. Emergent Biosolutions shares last traded at $12.08, with a volume of 1,263,793 shares trading hands.

Analyst Upgrades and Downgrades

EBS has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a report on Tuesday, December 16th. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. Wall Street Zen upgraded Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $15.00.

Emergent Biosolutions Stock Up 5.0%

The stock has a market capitalization of $634.44 million, a price-to-earnings ratio of 9.29 and a beta of 2.30. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. The business’s 50-day moving average is $11.74 and its two-hundred day moving average is $9.65.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.18. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The company had revenue of $231.10 million during the quarter, compared to the consensus estimate of $203.67 million. Equities analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Activity at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the transaction, the director owned 98,417 shares in the company, valued at approximately $1,178,051.49. This trade represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Emergent Biosolutions

A number of hedge funds and other institutional investors have recently modified their holdings of EBS. Assenagon Asset Management S.A. raised its holdings in shares of Emergent Biosolutions by 2.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 57,805 shares of the biopharmaceutical company’s stock worth $714,000 after acquiring an additional 1,350 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Emergent Biosolutions by 14.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 1,625 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in Emergent Biosolutions by 14.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,204 shares during the period. Cetera Investment Advisers boosted its holdings in Emergent Biosolutions by 0.7% in the 2nd quarter. Cetera Investment Advisers now owns 358,952 shares of the biopharmaceutical company’s stock valued at $2,290,000 after purchasing an additional 2,671 shares during the last quarter. Finally, Profund Advisors LLC boosted its holdings in Emergent Biosolutions by 23.9% in the 3rd quarter. Profund Advisors LLC now owns 20,425 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 3,937 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.